During FY22-25, Safari Industries recorded a CAGR of 36%/60%/65% in revenue/Ebitda/PAT, with a 12.7% Ebitda margin. The brokerage models a revenue/ Ebitda/APAT CAGR of 16%/25%/27% over FY25-FY28, led by volume growth and an improving margin profile.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Safari Industries India Ltd., a leading player in the mass-luggage industry with ~30% share between the top three players, has outpaced industry growth and reported a revenue CAGR of 36% over FY22-25.
During FY22-25, Safari Industries recorded a CAGR of 36%/60%/65% in revenue/Ebitda/PAT, with a 12.7% Ebitda margin. We model a revenue/ Ebitda/APAT CAGR of 16%/25%/27% over FY25-FY28, led by volume growth and an improving margin profile.
Management aims to double revenue (Rs 40 billion) over the next four-five years while maintaining gross margins of ~45- 47% and Ebitda margins of ~14-16%, based on the current outlook.
We expect Safari Industries to deliver industry-beating growth and expand its market share by focusing on-
building the Urban Jungle brand along with Safari Industries-Select (premium positioning),
ramping up capacity utilization at Jaipur,
developing in-house manufacturing of ancillary components, and
adding 50 exclusive brand outlets every year.
With strong operating performance, improving free cash flow to Rs 2.7 billion in FY28E, and an expansion in RoE to 19.4% in FY28E from 16.1% in FY25, we reiterate our Buy rating with a DCF-based target price of Rs 2,700 (based on an implied P/E of 50x on Sep’27).
Click on the attachment to read the full report:
Also Read: Sun Pharma Is Well Poised To Sustain Growth In Focus Segments, Says Motilal Oswal Maintaining 'Buy'
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Sun Pharma Is Well Poised To Sustain Growth In Focus Segments, Says Motilal Oswal Maintaining 'Buy'


VIP, Safari Industries Gets Motilal Oswal's 'Buy' Rating As It Initiates Coverage


Reliance Industries Setting The Stage For Multi-Decadal Value Creation, Says Motilal Oswal Maintaining 'Buy'


Nirmal Bang Remains Structurally Positive On Indoco Remedies; Maintains 'Hold' Rating — Check Target Price
